| IL1β promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D M Kiss, L Vande Walle, PHV Saavedra, E Lebegge, H Van Damme, ... Cancer immunology research 9 (3), 309-323, 2021 | 51 | 2021 |
| Targeted repolarization of tumor‐associated macrophages via imidazoquinoline‐linked nanobodies E Bolli, M Scherger, SM Arnouk, AR Pombo Antunes, D Straßburger, ... Advanced Science 8 (10), 2004574, 2021 | 48 | 2021 |
| Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors E Bolli, M D’Huyvetter, A Murgaski, D Berus, G Stangé, EJ Clappaert, ... Journal of controlled release 314, 1-11, 2019 | 26 | 2019 |
| Innate immune defense mechanisms by myeloid cells that hamper cancer immunotherapy E Lebegge, SM Arnouk, PMR Bardet, M Kiss, G Raes, ... Frontiers in Immunology 11, 549487, 2020 | 16 | 2020 |
| Unleashing tumour-dendritic cells to fight cancer by tackling their three A’s: abundance, activation and antigen-delivery A Murgaski, PMR Bardet, SM Arnouk, EJ Clappaert, D Laoui Cancers 11 (5), 670, 2019 | 16 | 2019 |
| Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages A Murgaski, M Kiss, H Van Damme, D Kancheva, I Vanmeerbeek, ... Cancer Research 82 (20), 3785-3801, 2022 | 14 | 2022 |
| Transient multivalent nanobody targeting to CD206-expressing cells via PH-degradable nanogels M Scherger, E Bolli, ARP Antunes, S Arnouk, J Stickdorn, ... Cells 9 (10), 2222, 2020 | 13 | 2020 |
| Imaging and therapeutic targeting of the tumor immune microenvironment with biologics S Arnouk, TWM De Groof, JA Van Ginderachter Advanced Drug Delivery Reviews 184, 114239, 2022 | 8 | 2022 |
| Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting M Erreni, F D'Autilia, R Avigni, E Bolli, SM Arnouk, K Movahedi, P Debie, ... Theranostics 13 (1), 355, 2023 | 7 | 2023 |
| Self‐Immolative Nanobody‐Cysteine Residue Modification for Controlled Immunodrug Delivery M Scherger, YA Pilger, J Stickdorn, P Komforth, S Schmitt, SM Arnouk, ... Advanced Therapeutics 6 (11), 2300076, 2023 | 2 | 2023 |
| Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment M Kiss, E Lebegge, A Murgaski, H Van Damme, D Kancheva, ... Frontiers in immunology 13, 1003975, 2022 | 2 | 2022 |
| Nanobody-mediated targeting of immunoregulatory cells for cancer therapy S Arnouk | | 2023 |
